{"id":130453,"date":"2022-06-02T07:56:53","date_gmt":"2022-06-02T11:56:53","guid":{"rendered":"https:\/\/44.250.171.167\/?p=130453"},"modified":"2022-10-06T04:27:10","modified_gmt":"2022-10-06T08:27:10","slug":"glenmark-pharmaceuticals-limited-q4-fy22-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-limited-q4-fy22-earnings-conference-call-insights\/","title":{"rendered":"Glenmark Pharmaceuticals Limited Q4 FY22 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Glenmark Pharmaceuticals Limited Q4 FY22 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/uTUQ9VpSoiU?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Glenmark Pharmaceuticals Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/GLENMARK\/\">GLENMARK<\/a>) Q4 FY22 Earnings Concall<\/strong><\/p>\n<p><strong>Management Update:<\/strong><\/p>\n<ul>\n<li>GLENMARK said the India business continues to significantly outperform industry growth rates, continuing the trend of the past several years.<\/li>\n<\/ul>\n<ul>\n<li>The company said it filed a total of 19 ANDA applications with the U.S. FDA in FY22 and plans to file 14 to 15 ANDAs in FY &#8217;23.<\/li>\n<\/ul>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Damayanti Kerai from HSBC Securities asked about the update on Monroe; remediation and sales pickup expectation. Glenn Saldanha MD said GLENMARK recently had an FDA inspection, and it had 17 observations that came out of Monroe. GLENMARK is confident of addressing some of these observations and post that, it will start commercializing products from Monroe.<\/li>\n<\/ul>\n<ul>\n<li>Damayanti Kerai from HSBC Securities asked about the US pricing environment. Glenn Saldanha MD replied that the U.S. pricing environment continues to stay challenging. GLENMARK continues to see around high single-digit price erosion in the U.S. And the company expects this to continue into next year.<\/li>\n<\/ul>\n<ul>\n<li>Damayanti Kerai from HSBC Securities asked about the reason for high amount of other income in 4Q. Glenn Saldanha MD said the other income basically had an exchange gain of INR92 crores, which was the reason for the high amount.<\/li>\n<\/ul>\n<ul>\n<li>Saion Mukherjee from Nomura asked about the total cost incurred in the P&amp;L from the Monroe side in FY22 and the expected cost in FY23. Glenn Saldanha MD said it spent about $30 million in Monroe last year, out of which about $10 million hits the P&amp;L. In FY23 it is expected to go lower in FY23.<\/li>\n<\/ul>\n<ul>\n<li>Shyam Srinivasan from Goldman Sachs asked about the reason for dragging down of revenue growth. Glenn Saldanha MD answered that the 6% to 8% is because of the high base of COVID drugs that GLENMARK has in this year. Stripping that out, it&#8217;s double-digit growth.<\/li>\n<\/ul>\n<ul>\n<li>Shyam Srinivasan from Goldman Sachs asked about the driver of EBITDA margin and if it can be taken beyond 20%. V. S. Mani CFO said the company wanted to guide to a very realistic number. Since there is some amount of uncertainty everywhere, GLENMARK thought to guide to 19% rather than to say anything more than that.<\/li>\n<\/ul>\n<ul>\n<li>Sameer Baisiwala from Morgan Stanley asked about the kind of deleveraging the company is looking at for FY23. V. S. Mani CFO said it would not like to really put a number out. GLENMARK would definitely guide that it wants to reduce it further, but would not want to put a broad number there.<\/li>\n<\/ul>\n<ul>\n<li>Sameer Baisiwala from Morgan Stanley enquired about the specific timeline for Ryaltris U.S. launch. Glenn Saldanha MD clarified that it will most likely be second half this year.<\/li>\n<\/ul>\n<ul>\n<li>Nitin Agarwal from DAM Capital asked about the broad breakup of capex guidance of INR700-800 crores for FY23. Glenn Saldanha MD said that the company is having a number of brownfield and greenfield projects in its GLS, which should be about INR200 crore plus. The remaining would be some in-licensing spends and some normal capex in GPL and R&amp;D side.<\/li>\n<\/ul>\n<ul>\n<li>Nitin Agarwal from DAM Capital enquired about the total capex investment in Monroe so far. Glenn Saldanha MD replied that so far the company has spent almost about $200 million on all the three lines put together over the years.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Glenmark Pharmaceuticals Limited (GLENMARK) Q4 FY22 Earnings Concall Management Update: GLENMARK said the India business continues to significantly outperform industry growth rates, continuing the trend of the past several years. The company said it filed a total of 19 ANDA applications with the U.S. FDA in FY22 and plans to file 14 [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[1115],"class_list":["post-130453","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":127598,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-limited-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":130453,"position":0},"title":"Glenmark Pharmaceuticals Limited Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 16, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=Mzpw87FqOBE Key highlights from Glenmark Pharmaceuticals Limited (GLENMARK) Q3 FY22 Earnings Concall Management Update: GLENMARK stated the India business continues to outperform the industry growth and is growing consistently. In North America, GLENMARK filed 13 ANDA applications with FDA in nine month FY22 and is on track to file around\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":128559,"url":"https:\/\/alphastreet.com\/india\/glenmark-life-sciences-limited-q4-fy22-earnings-conference-call-summary\/","url_meta":{"origin":130453,"position":1},"title":"Glenmark Life Sciences Limited Q4 FY22 Earnings Conference Call Summary","author":"Praveen","date":"April 21, 2022","format":false,"excerpt":"https:\/\/youtu.be\/au71QUL41tY Key highlights from Glenmark Life Sciences Limited (GLS) Q4 FY22 Earnings Concall Q&A Highlights: Neha Manpuria of Bank of America asked if GLS is seeing any issues relative to sourcing of raw materials due to lockdown in China. Yasir Rawjee MD said that the crisis is unlikely to impact\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":156221,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-limited-q2-fy24-earnings-conference-call-insights\/","url_meta":{"origin":130453,"position":2},"title":"Glenmark Pharmaceuticals Limited Q2 FY24 Earnings Conference Call Insights","author":"Praveen","date":"November 15, 2023","format":false,"excerpt":"Key highlights from Glenmark Pharmaceuticals Limited (GLENMARK) Q2 FY24 Earnings Concall Financial Results Revenue increased 6.3% YoY to INR35,879 million. India formulation sales grew 2.8% YoY despite market slowdown. North America sales declined 1.9% YoY. Europe sales increased 58.4% YoY on branded business growth. ROW sales grew 19% YoY across\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":146758,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-glenmark-pharmaceuticals-limited-for-q4-fy23\/","url_meta":{"origin":130453,"position":3},"title":"Earnings Summary Of Glenmark Pharmaceuticals Limited For Q4 FY23","author":"Hardik Bhandare","date":"May 19, 2023","format":false,"excerpt":"Glenmark Pharmaceuticals Limited is a global pharmaceutical company headquartered in Mumbai, India. Established in 1977, the company has grown to become a leading player in the pharmaceutical industry, with a presence in over 80 countries worldwide. Glenmark focuses on developing and manufacturing innovative and affordable pharmaceutical products across various therapeutic\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-5-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":147179,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-limited-q4-fy23-earnings-conference-call-insights\/","url_meta":{"origin":130453,"position":4},"title":"Glenmark Pharmaceuticals Limited Q4 FY23 Earnings Conference Call Insights","author":"Praveen","date":"May 24, 2023","format":false,"excerpt":"Key highlights from Glenmark Pharmaceuticals Limited (GLENMARK) Q4 FY23 Earnings Concall Q&A Highlights: [00:27:19] Tushar Manudhane at Motilal Oswal asked about the INR220 crores and INR91 crores remediation cost in terms of infrastructure investment and quality. V. S. Mani Global CFO said 12 people worked at sites in India and\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":142579,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-glenmark-pharmaceuticals-limited-for-q3-fy23\/","url_meta":{"origin":130453,"position":5},"title":"Earnings Summary Of Glenmark Pharmaceuticals Limited For Q3 FY23","author":"Hardik Bhandare","date":"February 23, 2023","format":false,"excerpt":"Glenmark Pharmaceuticals Limited (NSE: GLENMARK) is a global research-driven pharmaceutical company that develops and markets innovative drugs for major therapeutic areas such as dermatology, respiratory, oncology, and diabetes. The company operates in over 80 countries and has manufacturing facilities in India, Switzerland, and Argentina. The company's revenue is primarily generated\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-20.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/130453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=130453"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/130453\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=130453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=130453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=130453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}